REYKJAVIK,Iceland,Feb. 24,2025 -- 3Z Pharmaceuticals,aCNS-focused therapeutic development specialist,today announced the publication of a groundbreaking study in The Journal of Pharmacology and Experimental Therapeutics,unveiling novel insights into the metabolic mechanisms of ADHD treatments. This research,utilizing untargeted metabolomic and lipidomic profiling,addresses a critical knowledge gap in ADHD treatment. It reveals a convergence of molecular pathways among stimulant and non-stimulant ADHD medications and supports 3Z's earlier announced discovery of amlodipine as an L-type calcium channel blocker candidate.

ADHD is a highly prevalent neurodevelopmental disorder with complex underlying mechanisms and limited treatment options. While both stimulant and non-stimulant medications are widely used,their precise metabolic effects on the brain remain poorly understood.

"This study represents a major leap forward in our understanding of ADHD therapeutics," commented Dr. Karl Karlsson,CEO of 3Z Pharmaceuticals,emphasizing the study's significance,"By leveraging advanced metabolomics and lipidomics,we have uncovered a shared metabolic signature across treatments—highlighting the potential of L-type calcium channel modulation as the foundation for a new non-stimulant ADHD therapy. These findings not only validate our drug discovery platform but also pave the way for much-needed new treatment options."

To bridge this gap,3Z Pharmaceuticals employed an advanced systems biology approach,integrating cross-species analysis using the zebrafish adgrl3.1 ADHD model with targeted metabolomic profiling to explore common metabolic pathways underlying ADHD therapeutics.

Key Findings from the Study:

Metabolic Pathway Convergence:The study demonstrated that existing ADHD treatments—methylphenidate,guanfacine,and atomoxetine—as well as the novel candidate amlodipine,modulate share metabolic pathways related to amino acid and lipid metabolism. These include glycine,serine,threonine,lysophosphatidylcholine,and sphingomyelin metabolism.

Systemic impact: Rather than acting through distinct,isolated mechanisms,ADHD medications appear to exert a broader,systemic impact on neurotransmitter precursors,oxidative stress markers,and energy metabolism.

Amlodipine's Overlapping Effects with ADHD Medications:The metabolic profile of amlodipine significantly overlapped with that of established ADHD treatments,supporting L-type calcium channel engagement as a potential therapeutic pathway for ADHD.

Full Study: https://www.sciencedirect.com/science/article/pii/S0022356525396163

Building on these findings,3Z Pharmaceuticals is advancing its metabolomics-driven approach to CNS drug discovery,focusing on refining therapeutic targets and optimizing treatment strategies for future clinical development.

About 3Z Pharmaceuticals

3Z Pharmaceuticals,based in Reykjavik,identifies and advances next-generation therapiesfor CNS disorders throughboth novel discovery and strategic repurposing. The company is pioneering astate-of-the-art drug development platformthat integrateshigh-throughput screening,multi-omics,and AI analytics.

With a strong focus ontranslational validation,3Z de-risks CNS drug development by combiningmulti-species assessment with human Mendelian randomization,polygenic risk scoring,and genetic studiesto enhance clinical predictability.

Contact

For more information or media inquiries,please contact:

Karl Karlsson

CEO,3Z Pharmaceuticals

Karlsson@3z.is

DD:+354 825 66467

This information was brought to you by Cision http://news.cision.com

https://news.cision.com/3z-ehf/r/3z-pharmaceuticals-publishes-breakthrough-study-on-shared-metabolic-pathways-in-adhd-therapeutics,c4110316